This is similar to other ongoing phase 3 registration trials in nephrology (Atrasentan in Patients With IgA [Immunoglobulin A] Nephropathy [ALIGN]32 and A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure [ARCTIC]).33 This approach, validated by analyses of past trials, allows for accurate assessment of treatment effects on the eGFR slope.27 This evidence concerns the gene CD79A and hypertensive disorder.